Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea

NCT01929291 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01929291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01929291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
September 23, 2013
Completion date
January 11, 2016
Enrollment
682 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria-tetanus-acellular pertussis vaccines